|
Αρχειοθήκη ιστολογίου
-
►
2023
(269)
- ► Φεβρουαρίου (133)
- ► Ιανουαρίου (136)
-
►
2022
(2046)
- ► Δεκεμβρίου (165)
- ► Σεπτεμβρίου (161)
- ► Φεβρουαρίου (165)
-
▼
2021
(3028)
- ► Δεκεμβρίου (135)
- ► Σεπτεμβρίου (182)
-
▼
Μαρτίου
(306)
-
▼
Μαρ 21
(17)
- Prevalence and pubo-umbilical index of pyramidalis...
- Propranolol versus nadolol for treatment of pediat...
- Propranolol versus nadolol for treatment of pediat...
- Immunotherapy for head and neck cancer: from recur...
- Bioengineering for head and neck reconstruction: t...
- Molecular analysis of fine-needle aspiration cytol...
- Videomics: bringing deep learning to diagnostic en...
- Indications and limits of postoperative radiothera...
- Immediate dental implant placement and restoration...
- Nasal vestibule and columella cancer: a therapeuti...
- Treatment of persistent/recurrent nodal disease in...
- Imaging-based navigation technologies in head and ...
- Current indications for adjuvant treatment followi...
- Therapeutic challenges in radiation-induced saliva...
- A roadmap of six different pathways to improve sur...
- Oral potentially malignant disorders: new insights...
- Precision head and neck surgery: robotics and surg...
-
▼
Μαρ 21
(17)
- ► Φεβρουαρίου (324)
-
►
2020
(1051)
- ► Δεκεμβρίου (292)
- ► Σεπτεμβρίου (60)
- ► Φεβρουαρίου (28)
-
►
2019
(2277)
- ► Δεκεμβρίου (18)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (89)
-
►
2018
(26280)
- ► Δεκεμβρίου (189)
- ► Φεβρουαρίου (6130)
- ► Ιανουαρίου (7050)
-
►
2017
(33948)
- ► Δεκεμβρίου (6715)
- ► Σεπτεμβρίου (6470)
-
►
2016
(4179)
- ► Σεπτεμβρίου (638)
- ► Φεβρουαρίου (526)
- ► Ιανουαρίου (517)
Κυριακή 21 Μαρτίου 2021
Prevalence and pubo-umbilical index of pyramidalis muscle in a select Kenyan population
Propranolol versus nadolol for treatment of pediatric subglottic hemangioma,,,,,Nadolol is a non-selective β-adrenergic antagonist that lacks intrinsic sympathomimetic activity and membrane-stabilizing properties. Nadolol is two to four times more potent than propranolol. The drug reduces IOP when administered topically in a concentration of 0.3–2%160 or orally in a dose of 20–40 mg. Nadolol - an overview | ScienceDirect Topicswww.sciencedirect.com › topics › neuroscience › nadolol
|
Propranolol versus nadolol for treatment of pediatric subglottic hemangioma
|
Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors
|
Bioengineering for head and neck reconstruction: the role of customized flaps
|
Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we?
|
Videomics: bringing deep learning to diagnostic endoscopy
|
Indications and limits of postoperative radiotherapy for skin malignancies
|
Immediate dental implant placement and restoration in the edentulous mandible in head and neck cancer patients: a systematic review and meta-analysis
|
Nasal vestibule and columella cancer: a therapeutic and reconstructive conundrum
|
Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer
|